Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas

Journal of Clinical Oncology

Volumn 20, Issue 5, 2002, Pages 1389-1397

  Reardon, David A ^a   Akabani, Gamal ^a   Coleman, R Edward ^a   Friedman, Allan H ^a   Friedman, Henry S ^a   Herndon II, James E ^a   Cokgor, Ilkcan ^a   McLendon, Roger E ^a   Pegram, Charles N ^a   Provenzale, James M ^a   Quinn, Jennifer A ^a   Rich, Jeremy N ^a   Regalado, Lorna V ^a   Sampson, John H ^a   Shafman, Timothy D ^a   Wikstrand, Carol J ^a   Wong, Terence Z ^a   Zhao, Xiao Guang ^a   Zalutsky, Michael R ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY 81C6 I 131; MONOCLONAL ANTIBODY I 131; TENASCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG ABSORPTION; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HEMATOLOGIC DISEASE; HUMAN; MALE; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION NECROSIS; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ASTROCYTOMA; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOTHERAPY; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; SURVIVAL RATE; TENASCIN; TREATMENT OUTCOME;

EID: 0036498790     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.5.1389     Document Type: Article

References (41)

1. Neurooncology index and review (adult primary brain tumors): Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy
2. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials
3. Supratentorial malignant glioma: Patterns of recurrence and implications for external beam local treatment
4. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2: A preliminary report
5. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results
6. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas
7. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody
8. Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein
9. Tenascin expression in human glioma cell lines and normal tissues
10. Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies
11. Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: Paired-label and imaging analysis
12. The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice
13. Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration
14. Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model
15. Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma
16. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors
17. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations
18. Nonparametric estimation from incomplete observations
19. Evaluation of survival data and two new rank order statistics arising in its consideration
20. Regression models and life tables
21. Chimeric anti-tenascin antibody 81C6: Increased tumor localization compared with its murine parent
22. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results
23. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy
24. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials
25. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: A six-year clinical experience
26. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: A phase I study
27. Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: Feasibility, pharmacokinetics and dosimetry
28. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates
29. External irradiation followed by an interstitial high activity iodine-125 "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2
30. Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme
31. Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas
32. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma
33. Brachytherapy: Results of two different therapy strategies for patients with primary glioblastoma multiforme
34. High activity iodine-125 interstitial implant for gliomas
35. Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas
36. Results of stereotactic brachytherapy used in initial management of patients with glioblastoma
37. Stereotactic radiosurgery for intracranial malignancies
38. Stereotactic radiosurgery for glioblastoma: A final report of 31 patients
39. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme
40. Placebo controlled multicenter double-blind randomized prospective phase III trial of carmustine implants (Gliadel) in 240 patients with malignant gliomas: Final results